Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Omalizumab, both as a monotherapy and for oral immunotherapy (OIT), modulates specific T cell and dendritic cell (DC) subsets, increasing patient's reaction thresholds to common food allergens, ...